Patents by Inventor Hyori KIM
Hyori KIM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240082305Abstract: Antibody-mediated rejection (ABMR) is one of the main obstacles to successful transplantation, including ABO blood group-incompatible (ABOi) transplantation. C4d deposition is a marker of ABMR and is also found in most ABOi allograft tissues. Described herein are anti-C4d CAR Tregs that suppress ABMR in ABOi allografts. Anti-C4d CAR Tregs prepared by retroviral transduction of CAR into CD62L +CD4 +CD25 +Tregs, expressed Foxp3, CD25, CTLA-4, LAP, and GITR to similar extents as non-transduced Tregs. Anti-C4d CAR Tregs were activated by specific binding to C4d and suppressed in vitro T cell proliferation as well as non-transduced Tregs. Furthermore, adoptive transfer of anti-C4d CAR Tregs significantly prolonged mouse ABOi heart allograft survival (P<0.05).Type: ApplicationFiled: January 20, 2022Publication date: March 14, 2024Inventors: Jaeseok YANG, Sun-Kyung LEE, Joon Young JANG, Junho CHUNG, Jerome HAN, Nara SHIN, Hyori KIM
-
Publication number: 20230242670Abstract: The present invention relates to an anti-ROS1 antibody improved in specificity for ROS1 and a use thereof and, more particularly, provides an anti-ROS1 antibody or an antigen-binding fragment thereof and a use thereof in cancer diagnosisType: ApplicationFiled: March 6, 2018Publication date: August 3, 2023Inventors: Junho CHUNG, Eugene C. Yl, Ji Eun KIM, Hwa Kyoung LEE, Junyeong JIN, Jong Bae PARK, Hyori KIM
-
Patent number: 11707486Abstract: Disclosed are a natural killer (NK) cell expressing an anti-cotinine chimeric antigen receptor (CAR) specifically binding to cotinine, and a cell therapeutic agent containing the NK cell. The CAR-expressing NK cell which specifically binds cotinine, can effectively move to tumor tissue, regardless of the kind of cancer, depending on the binding substance bound to cotinine. Therefore, the natural killer cell can be usefully employed as a gene therapy exhibiting a highly efficient anticancer effect.Type: GrantFiled: July 5, 2019Date of Patent: July 25, 2023Assignees: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY, SEOUL NATIONAL UNIVERSITY R&DB FOUNDATIONInventors: In Pyo Choi, Tae-Don Kim, Su Ui Lee, Sooyun Lee, Junho Chung, Ki-Hyun Kim, Hyori Kim
-
Publication number: 20230017956Abstract: A chimeric antibody receptors with anti-cotinine antibodies linked, and uses thereof are disclosed. A T cell presenting the chimeric antibody receptor on the surface secretes interferon gamma specifically for a target molecule of a cotinine-conjugated binding molecule that is added together therewith and induces cell death of the cell expressing the target molecule by the T cell. On the contrary, by administering a cytotoxic agent conjugated with cotinine, cell death of the chimeric antigen receptor T cell is induced. Therefore, if necessary, a cytotoxic agent conjugated with cotinine can be administered to remove the chimeric antigen receptor T cells that have been already administered, thereby suppressing immune side effects due to hyperactivity of T cells. Thus, the chimeric antigen receptor to which the anti-cotinine antibody is linked can be effectively and safely used for the treatment of cancer.Type: ApplicationFiled: August 31, 2022Publication date: January 19, 2023Applicant: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATIONInventors: Kyungho CHOI, Hyung-Bae Park, Ji Eun Lee, Yumi Oh, Ki-Hyun Kim, Soohyun Kim, Hyori Kim, Junho Chung
-
Patent number: 11478555Abstract: The present invention relates to chimeric antibody receptors with anti-cotinine antibodies linked, and use thereof. A T cell presenting the chimeric antibody receptor on the surface secretes interferon gamma specifically for a target molecule of a cotinine-conjugated binding molecule that is added together therewith and induces cell death of the cell expressing the target molecule by the T cell. On the contrary, by administering a cytotoxic agent conjugated with cotinine, cell death of the chimeric antigen receptor T cell is induced. Therefore, if necessary, a cytotoxic agent conjugated with cotinine can be administered to remove the chimeric antigen receptor T cells that have been already administered, thereby suppressing immune side effects due to hyperactivity of T cells. Thus, the chimeric antigen receptor to which the anti-cotinine antibody is linked can be effectively and safely used for the treatment of cancer.Type: GrantFiled: August 17, 2016Date of Patent: October 25, 2022Assignee: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATIONInventors: Kyungho Choi, Hyung-Bae Park, Ji Eun Lee, Yumi Oh, Ki-Hyun Kim, Soohyun Kim, Hyori Kim, Junho Chung
-
Patent number: 11339210Abstract: The present invention relates to an antibody against C5, and a method for preventing and treating complement-related diseases using the antibody, wherein the antibody against C5 is effectively usable in preventing and treating complement-related diseases by inhibiting complement activation.Type: GrantFiled: April 18, 2019Date of Patent: May 24, 2022Assignee: Seoul National University R&DB FoundationInventors: Junho Chung, Hyori Kim, Hwa Kyoung Lee, Won Jun Yang
-
Publication number: 20220089774Abstract: The present invention relates to a monoclonal antibody which specifically binds to an EGF2 domain of colon cancer secreted protein-2 (CCSP-2), or an antigen-binding fragment thereof. The monoclonal antibody or the antigen-binding fragment thereof of the present invention specifically binds to the EGF2 domain of CCSP-2, and thus has significantly increased affinity compared with existing peptides specifically binding to CCSP-2 and further increased specificity compared with existing antibodies to CCSP-2. Therefore, in future, accurate diagnosis can be achieved by specific detection of CCSP-2 in the protein level.Type: ApplicationFiled: January 29, 2020Publication date: March 24, 2022Applicants: THE ASAN FOUNDATION, EDISBIOTECH CO., LTD., UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATIONInventors: Seung-Jae MYUNG, Eun-Ju DO, Jayoung KANG, Hye-Nam SON, Hyori KIM, A-Neum LEE, Yeong Hui CHO
-
Publication number: 20210371536Abstract: The present invention relates to an antibody against a PDGF receptor, an antibody-drug conjugate in which a chemotherapeutic agent is conjugated to the antibody against PDGF receptor, and a use of prevention or treatment of ocular neovascular diseases.Type: ApplicationFiled: October 7, 2019Publication date: December 2, 2021Inventors: Soohyun KIM, Hyori KIM, Dong Hyun JO, Jeong Hun KIM, Suree KIM, Dongmin KANG, Dobeen HWANG, Junho CHUNG
-
Patent number: 11167037Abstract: The present invention relates to an antibody drug conjugate using a bispecific antibody and its use. The antibody drug conjugate of the present invention can easily form a conjugate of an antibody and a drug without a multistep synthetic process though binding of a conjugate of a bivalent cotinine-peptide and a drug, and an anti-cotinine single chain variable fragment. In addition, the antibody drug conjugate can effectively deliver a drug to a target to which the antibody binds specifically, and can enhance a half-life of a drug in the body, thereby improving a therapeutic effect.Type: GrantFiled: June 21, 2017Date of Patent: November 9, 2021Assignee: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATIONInventors: Junho Chung, Junyeong Jin, Hyori Kim, Gunwoo Park, Soohyun Kim
-
Publication number: 20210171611Abstract: The present invention relates to an antibody which specifically binds to the envelope glycoprotein of severe fever with thrombocytopenia syndrome virus (SFTSV), the pathogen of severe fever with thrombocytopenia syndrome (SFTS), and is used in order to effectively detect or diagnosis SFTSV and treat SFTS.Type: ApplicationFiled: February 9, 2021Publication date: June 10, 2021Inventors: Junho CHUNG, Ki-Hyun KIM, Hyori KIM, Myoung-don OH, Wan Beom PARK, Seungtaek KIM, Jinhee KIM, Ji-Young MIN, Meehyun KO
-
Patent number: 10947299Abstract: The present invention relates to an antibody which specifically binds to the envelope glycoprotein of severe fever with thrombocytopenia syndrome virus (SFTSV), the pathogen of severe fever with thrombocytopenia syndrome (SFTS), and is used in order to effectively detect or diagnosis SFTSV and treat SFTS.Type: GrantFiled: March 23, 2017Date of Patent: March 16, 2021Assignees: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, INSTITUT PASTEUR KOREAInventors: Junho Chung, Ki-Hyun Kim, Hyori Kim, Myoung-don Oh, Wan Beom Park, Seungtaek Kim, Jinhee Kim, Ji-Young Min, Meehyun Ko
-
Publication number: 20190382472Abstract: The present invention relates to an antibody against C5, and a method for preventing and treating complement-related diseases using the antibody, wherein the antibody against C5 is effectively usable in preventing and treating complement-related diseases by inhibiting complement activation.Type: ApplicationFiled: April 18, 2019Publication date: December 19, 2019Applicant: Seoul National University R&DB FoundationInventors: Junho Chung, Hyori Kim, Hwa Kyoung Lee, Won Jun Yang
-
Publication number: 20190328894Abstract: The present invention relates to an antibody drug conjugate using a bispecific antibody and its use. The antibody drug conjugate of the present invention can easily form a conjugate of an antibody and a drug without a multistep synthetic process though binding of a conjugate of a bivalent cotinine-peptide and a drug, and an anti-cotinine single chain variable fragment. In addition, the antibody drug conjugate can effectively deliver a drug to a target to which the antibody binds specifically, and can enhance a half-life of a drug in the body, thereby improving a therapeutic effect.Type: ApplicationFiled: June 21, 2017Publication date: October 31, 2019Applicants: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, SEOUL NATIONAL UNIVERSITY R&DB FOUNDATIONInventors: Junho CHUNG, Junyeong JIN, Hyori KIM, Gunwoo PARK, Soohyun KIM
-
Patent number: 10280215Abstract: The present invention relates to an antibody against C5, and a method for preventing and treating complement-related diseases using the antibody, wherein the antibody against C5 is effectively usable in preventing and treating complement-related diseases by inhibiting complement activation.Type: GrantFiled: February 3, 2014Date of Patent: May 7, 2019Assignee: Seoul National University R&DB FOUNDATIONInventors: Junho Chung, Hyori Kim, Hwa Kyoung Lee, Won Jun Yang
-
Publication number: 20190112360Abstract: The present invention relates to an antibody which specifically binds to the envelope glycoprotein of severe fever with thrombocytopenia syndrome virus (SFTSV), the pathogen of severe fever with thrombocytopenia syndrome (SFTS), and is used in order to effectively detect or diagnosis SFTSV and treat SFTS.Type: ApplicationFiled: March 23, 2017Publication date: April 18, 2019Inventors: Junho CHUNG, Ki-Hyun KIM, Hyori KIM, Myoung-don OH, Wan Beom PARK, Seungtaek KIM, Jinhee KIM
-
Publication number: 20180256744Abstract: The present invention relates to chimeric antibody receptors with anti-cotinine antibodies linked, and use thereof. A T cell presenting the chimeric antibody receptor on the surface secretes interferon gamma specifically for a target molecule of a cotinine-conjugated binding molecule that is added together therewith and induces cell death of the cell expressing the target molecule by the T cell. On the contrary, by administering a cytotoxic agent conjugated with cotinine, cell death of the chimeric antigen receptor T cell is induced. Therefore, if necessary, a cytotoxic agent conjugated with cotinine can be administered to remove the chimeric antigen receptor T cells that have been already administered, thereby suppressing immune side effects due to hyperactivity of T cells. Thus, the chimeric antigen receptor to which the anti-cotinine antibody is linked can be effectively and safely used for the treatment of cancer.Type: ApplicationFiled: August 17, 2016Publication date: September 13, 2018Applicant: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATIONInventors: Kyungho CHOI, Hyung-Bae PARK, Ji Eun LEE, Yumi OH, Ki-Hyun KIM, Soohyun KIM, Hyori KIM, Junho CHUNG
-
Publication number: 20160068592Abstract: The present invention relates to an antibody against C5, and a method for preventing and treating complement-related diseases using the antibody, wherein the antibody against C5 is effectively usable in preventing and treating complement-related diseases by inhibiting complement activation.Type: ApplicationFiled: February 3, 2014Publication date: March 10, 2016Applicant: Seoul National University R&DB FOUNDATIONInventors: Junho CHUNG, Hyori KIM, Hwa Kyoung LEE, Won Jun YANG